ที่ บช NO. AC. 04/2019 14 November 2019 Subject: Clarification of changes in operating performance of more than 20% To: The President of the Stock Exchange of Thailand M.K. Real Estate Development
/2561 June 19, 2018 Subject: Management’s discussion and analysis of the Company’s operating results for Q1/2018 period To: President The Stock Exchange of Thailand DOD Biotech Public Company Limited
/2561 August 7, 2018 Subject: Management’s discussion and analysis of the Company’s operating results for Q2/2018 period To: President The Stock Exchange of Thailand DOD Biotech Public Company Limited
วันที่ 14 สิงหาคม 2550 DEMCO Public Company Limited No. Demco AC003/2020 August 14, 2020 Subject : The company’s operating result for the quarter 2/2020 To : The president, The Stock Exchange of
Value -157.76 1,078.93 562.52 519.72 Other Operating Expenses 11,248.26 10,262.78 10,194.32 8,502.90 - Personnel Expenses 6,428.42 5,664.25 5,576.86 5,573.38 - Premises & Equip Expenses 1,003.04
delivering growth through Babi Mild and Twelve Plus, underpinned by strong brand equity and innovations that offer new benefits and exciting formats to customers. For international market, OSP continues to
. However, EBITDA declined by 5.8% yoy to THB 135 million due to higher administrative expenses and higher share of net losses from investments by the equity method. The Company reported net loss of THB 55
") would like to describe and analyze the financial position and operating results for year 2018 are summarized as follows. Performance Analysis From business operation of year 2018, the companies has
+ %')'#+"#$./+.'* !#[/+(#$PKL ,"' #$./+.'* % *#%"O* (cost income ratio) +" 58% %!' )'#+"#$O*./+bK$% *#%"O*P K 91% .')"#" &'.#% &P* M)* (return on equity) !+ %'#$./+.'*̀?#! #" !()*&'.#%&P* M)*P#$ 'M'#$./+.%O**! #" .''#$O*./+ ' 9
0.6% 545 1.0% (244) (44.7%) Profit for the period 890 1.6% 2,434 4.5% (1,544) (63.4%) Profit attributable to owners of the parent 743 1.4% 1,925 3.6% (1,182) (61.4%) Operating Information EBITDA 5,879